RevolKa is a biotech company pioneering the future through AI-powered protein engineering. Built on transparent management and a proven track record, we continue to grow together with our investors and partners.
The use of generative AI in biopharmaceuticals is rapidly expanding
Inefficient development processes that require years of trial and error and hundreds of millions of yen in investment.
Strong demand across pharmaceuticals, industrial enzymes, food, and environmental sectors.
(01)
By incorporating artificial intelligence — centered on machine learning — into directed evolution, we have developed a technology that explores a broader design space with greater accuracy and speed than ever before.
Learn more
(02)
Our team of experts brings proven achievements across AI, biology, and engineering. With global perspectives and deep expertise, we drive groundbreaking biotechnology forward.
Learn more
(03)
Our technology platform is backed by peer-reviewed publications and recognition at scientific conferences. From basic research to commercialization, we maintain a development approach that prioritizes scientific rigor.
Learn more
(04)
We are expanding our track record of adoption among major pharmaceutical and biotechnology companies. By dramatically reducing research timelines and costs, we have earned high acclaim from our partners.
Learn more
Our proprietary technology platform is backed by prominent partners in Japan and around the world.
※Investment order
